LONDON, Nov. 28, 2017 /PRNewswire/ — Download the full report: https://www.reportbuyer.com/product/5214363
According to the recently published report ‘Histone Deacetylase 4 – Pipeline Review, H2 2017’; Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 18.104.22.168) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes.
Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 22.214.171.124) – Histone deacetylase 4 (HDAC4) is a protein encoded by the HDAC4 gene. It is responsible for the deacetylation of lysine residues on the N-terminal part of the core histones. It plays an important role in transcriptional regulation, cell cycle progression and developmental events. It acts via the formation of large multiprotein complexes.
The report ‘Histone Deacetylase 4 – Pipeline Review, H2 2017’ outlays comprehensive information on the Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 126.96.36.199) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 188.8.131.52) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II and Preclinical stages are 1, 2 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular and Ophthalmology which include indications Bladder Cancer, Breast Cancer, Myelodysplastic Syndrome, Non-Small Cell Lung Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Bile Duct Cancer (Cholangiocarcinoma), Colon Cancer, Congestive Heart Failure (Heart Failure), Cutaneous T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Essential Thrombocythemia, Follicular Lymphoma, Gallbladder Cancer, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Leiomyosarcoma, Liver Cancer, Lung Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Pancreatic Cancer, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Prostate Cancer and Retinitis Pigmentosa (Retinitis).
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
– The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 184.108.40.206)
– The report reviews Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 220.127.116.11) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of